|
Sign In to gain access to subscriptions and/or personal tools.
|
Dietary Fish Oil and Cytokine and Eicosanoid Production During Human Immunodeficiency Virus Infection
Stacey J. Bell, DSc, RD
Surgical Metabolism Laboratory, Harvard Medical School, Boston, Massachusetts, Deaconess Hospital, Boston, Harvard Medical School, Boston, Massachusetts
Sambasiva Chavali, PHD
Surgical Metabolism Laboratory, Harvard Medical School, Boston, Massachusetts, Deaconess Hospital, Boston, Harvard Medical School, Boston, Massachusetts
Bruce R. Bistrian, MD, PHD
Deaconess Hospital, Boston, Harvard Medical School, Boston, Massachusetts, Nutrition and Infection Laboratory, Harvard Medical School, Boston, Massachusetts
Christine Apour Connolly, RD
Surgical Metabolism Laboratory, Harvard Medical School, Boston, Massachusetts, Division of General Surgery, Harvard Medical School, Boston, Massachusetts
Tohru Utsunomiya, MD
Surgical Metabolism Laboratory, Harvard Medical School, Boston, Massachusetts, Division of General Surgery, Harvard Medical School, Boston, Massachusetts
R. Armour Forse, MD, PHD
Surgical Metabolism Laboratory, Harvard Medical School, Boston, Massachusetts, Deaconess Hospital, Boston, Harvard Medical School, Boston, Massachusetts
Background : Dietary fish oil (FO) has been shown to modulate the immune system. The purpose of this study was to explore the effects of FO supplementation on the production of dienoic eicosanoids and cytokines in patients with human immunodeficiency virus (HIV) infection. Methods: This was a randomized, prospective, double-blind study that included homosexual males with HIV infection. Patients were asked to consume voluntarily five food bars daily containing FO (n = 10) or safflower oil (SO) (n = 9) for 6 weeks. At baseline and week 6, plasma was obtained to measure incorporation of -3 fatty acids. At baseline, week 3, and week 6, measurements were made of changes in dienoic eicosanoids and cytokines from lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMC) or spontaneously releasing cells. Results: In the FO group but not the SO group, there was increased incorporation of the -3 fatty acid docosahexaenoic acid (DHA) into the phospholipids of the fatty acids of the plasma. In the FO group, there was a significant decrease (p = .01) in 6-keto prostaglandin (PG) F 1 released from PBMC. There was a significant increase (p = .01) in interleukin (IL)-6 released from the PBMC in the FO group between baseline and week 3 and between week 3 and week 6. At week 6, there was significantly more IL-6 (p = .01) released from the PBMC in the FO group compared with the SO group. There was no change in CD4 cell counts by analysis of variance. Conclusions: The FO-containing food bars were well tolerated and allowed incorporation of -3 fatty acids to occur. Despite evidence of significant metabolic effects on eicosanoid and cytokine production, widespread clinical use of FO for HIV-infected patients is not warranted without further study, particularly given the trend toward a decline in CD4 cell numbers at this dose and with this type of fish oil. (Journal of Parenteral and Enteral Nutrition 20:43-49, 1996)
Journal of Parenteral and Enteral Nutrition, Vol. 20, No. 1,
43-49 (1996)
DOI: 10.1177/014860719602000143

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. R. Bistrian
Dietary Treatment in Secondary Wasting and Cachexia
J. Nutr.,
January 1, 1999;
129(1):
290S - 290S.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Klein, J. Kinney, K. Jeejeebhoy, D. Alpers, M. Hellerstein, M. Murray, and P. Twomey
Nutrition Support in Clinical Practice: Review of Published Data and Recommendations for Future Research Directions: Summary of a Conference Sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition
JPEN J Parenter Enteral Nutr,
May 1, 1997;
21(3):
133 - 156.
[Abstract]
[PDF]
|
 |
|
|
|